Qbic and PMV invest €500,000 in Pharmafluidics

The two firms each provided €250,000 in funding.

Qbic invested in the company via its Qbic Arkiv Fund, a joint venture capital vehicle with Arkimedes Fund II. The Arkimedes Fund II is a €100m Flemish fund-of-funds initiative that provides capital to match the amount already raised by a venture capital fund.

PMV provided capital via the €20m Sofi fund, a Flemish government-established fund that the state-backed firm manages.

The fresh capital provided to Pharmafluidics will be used to develop a set of commercial molecular separation columns for the industrials sector.

Company
Pharmafluidics was established as a spinout from Vrije Universiteit Brussel in 2010. The company is developing a new type of molecular separation column using high-performant liquid chromatography.

The business is initially using its technology to discover new biomarkers. Pharmafluidics offers its services to the chemicals and life sciences industries.

People
Paul Jacobs is the CEO of Pharmafluidics; he founded the company alongside scientific advisers Wim De Malsche, Gert Desmet and Joeri Denayer. Danny Gonnissen is an investment partner at Qbic; Ellen De Greve is an investment partner at PMV.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Benelux
• Expansion
• Industrials
• Belgium